Climb Bio (CLYM) – Analysts’ Recent Ratings Changes

Climb Bio (NASDAQ: CLYM) has recently received a number of price target changes and ratings updates:

• 9/16/2026 – Climb Bio was upgraded by Mizuho to “strong-buy”.
• 9/8/2026 – Climb Bio had its price target raised by Oppenheimer Holdings, Inc. from $18.00 to $25.00. They now have an “outperform” rating on the stock.
• 9/8/2026 – Climb Bio had its price target raised by HC Wainwright from $24.00 to $30.00. They now have a “buy” rating on the stock.
• 9/7/2026 – Climb Bio was upgraded by Mizuho to “strong-buy”.
• 9/4/2026 – Climb Bio had its “buy” rating reaffirmed by B. Riley Financial, Inc..
• 9/4/2026 – Climb Bio had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $30.00 price target on the stock, up from $26.00.
• 9/3/2026 – Climb Bio was given a new $40.00 price target by Piper Sandler. They now have an “overweight” rating on the stock.
• 9/3/2026 – Climb Bio had its price target raised by Robert W. Baird from $21.00 to $25.00. They now have an “outperform” rating on the stock.
• 9/3/2026 – Climb Bio had its price target raised by BTIG Research from $20.00 to $32.00. They now have a “buy” rating on the stock.
• 8/24/2026 – Climb Bio had its price target raised by HC Wainwright from $20.00 to $24.00. They now have a “buy” rating on the stock.
• 8/19/2026 – Climb Bio had its “outperform” rating reaffirmed by Wedbush. They now have a $20.00 price target on the stock.
• 8/7/2026 – Climb Bio had its price target raised by Truist Financial Corporation from $17.00 to $25.00. They now have a “buy” rating on the stock.
• 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $23.00 price target on the stock.
• 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set a “moderate buy” rating and a $23.00 price target on the stock.
• 7/27/2026 – Climb Bio had its price target raised by Wedbush from $17.00 to $20.00. They now have an “outperform” rating on the stock.

Insider Activity

In other news, Director Stephen Thomas sold 100,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total value of $1,367,000.00. Following the completion of the sale, the director owned 467,969 shares of the company’s stock, valued at approximately $6,397,136.23. This represents a 17.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.60% of the stock is currently owned by corporate insiders.

Climb Bio, Inc (NASDAQ: CLYM) is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research is centered on treatments intended to address conditions in which abnormal B-cell activity contributes to disease.

Climb Bio’s lead investigational program, CLYM-001, is a CD19-directed antibody designed to target and deplete B cells. The candidate is being developed for potential use in autoimmune and other immune-mediated disorders.